An Unexpected Tumor Reduction: Treatment with Olaparib Monotherapy in Heavily Pretreated BRCA2 Mutated Metastatic Pancreatic Cancer

PARP inhibitors are largely recognized as active drugs in BRCA-mutated breast and ovarian malignancies. In pancreatic ductal adenocarcinoma, the PARP inhibitor olaparib has recently been approved as maintenance treatment in patients with germline BRCA mutations reaching disease control after a plati...

Descripción completa

Detalles Bibliográficos
Autores principales: Prete, Alessandra Anna, Procaccio, Letizia, Bergamo, Francesca, Rasola, Cosimo, Nappo, Floriana, Zagonel, Vittorina, Lonardi, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870641/
https://www.ncbi.nlm.nih.gov/pubmed/35200549
http://dx.doi.org/10.3390/curroncol29020049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870641/
https://www.ncbi.nlm.nih.gov/pubmed/35200549
http://dx.doi.org/10.3390/curroncol29020049

Ejemplares similares